Aclaris Therapeutics, Inc. (ACRS) Shares Bought by Wells Fargo & Company MN

Wells Fargo & Company MN increased its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 230.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,883 shares of the biotechnology company’s stock after acquiring an additional 28,524 shares during the period. Wells Fargo & Company MN owned approximately 0.15% of Aclaris Therapeutics worth $1,109,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Franklin Resources Inc. grew its holdings in Aclaris Therapeutics by 55.4% during the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after acquiring an additional 697,104 shares during the period. FMR LLC grew its holdings in Aclaris Therapeutics by 253.1% during the first quarter. FMR LLC now owns 1,653,937 shares of the biotechnology company’s stock worth $49,321,000 after acquiring an additional 1,185,598 shares during the period. Eagle Asset Management Inc. grew its holdings in Aclaris Therapeutics by 287.3% during the second quarter. Eagle Asset Management Inc. now owns 1,357,973 shares of the biotechnology company’s stock worth $36,828,000 after acquiring an additional 1,007,343 shares during the period. Marshall Wace North America L.P. grew its holdings in Aclaris Therapeutics by 25.4% during the second quarter. Marshall Wace North America L.P. now owns 882,297 shares of the biotechnology company’s stock worth $23,822,000 after acquiring an additional 178,436 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Aclaris Therapeutics by 17.6% during the first quarter. Vanguard Group Inc. now owns 711,519 shares of the biotechnology company’s stock worth $21,218,000 after acquiring an additional 106,303 shares during the period. 95.83% of the stock is currently owned by hedge funds and other institutional investors.

ACRS has been the topic of a number of analyst reports. BidaskClub raised Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Jefferies Group LLC reissued a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research note on Monday, July 31st. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. JMP Securities reissued an “outperform” rating and issued a $39.00 price target on shares of Aclaris Therapeutics in a research note on Friday, September 8th. Finally, ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. Aclaris Therapeutics has a consensus rating of “Buy” and an average price target of $39.20.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.12.

ILLEGAL ACTIVITY NOTICE: “Aclaris Therapeutics, Inc. (ACRS) Shares Bought by Wells Fargo & Company MN” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/11/03/aclaris-therapeutics-inc-acrs-shares-bought-by-wells-fargo-company-mn.html.

In related news, Director Andrew N. Schiff bought 108,601 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were purchased at an average price of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 16.30% of the company’s stock.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

What are top analysts saying about Aclaris Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aclaris Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit